Insulet Q4 Earnings Call Highlights

Core Insights - Insulet achieved record new customer starts in Q4 and for the full year, with over 85% of new U.S. customers transitioning from multiple daily injections (MDI) and more than 40% being Type 2 diabetes patients [1][7] Financial Performance - For the full year, Insulet reported revenue exceeding $2.7 billion, reflecting a 29.5% increase in constant currency and a 30.7% increase reported [2] - Q4 total revenue was $784 million, up 29% on a constant currency basis and 31.2% reported, with U.S. revenue at $568 million (up 28%) and international revenue at $214 million (up 42% constant currency) [3][7] - The company has doubled its revenue base over the last three years, with U.S. revenue for 2025 at $1.9 billion (27.2% growth) and international revenue at $754 million (39.3% constant currency growth) [2] Profitability and Capital Allocation - Q4 gross margin was approximately 72.5%, with a full-year gross margin of 71.6%, reflecting improvements due to revenue growth and manufacturing productivity [5][12] - Adjusted EPS for Q4 was $1.55 (up 35% from $1.15 a year earlier) and $4.97 for the full year (up 53% from $3.24) [14] - The company ended the quarter with $760 million in cash and delivered over $375 million in free cash flow, with a $350 million share repurchase authorization approved [5][15][22] Market Dynamics - The U.S. Type 1 market is characterized as a $9 billion opportunity, with AID penetration around 40% compared to CGM penetration near 70% [8] - In the U.S. Type 2 market, AID penetration is below 5% in a market estimated at over $12 billion, with CGM adoption around 55% [9] - The prescriber base for Type 2 has grown 62% in 2025 to over 6,500 clinicians, emphasizing primary care as a key growth channel [9] Product Development and Expansion - Insulet is accelerating market expansion, with international Omnipod revenue growing 41.7% constant currency in Q4 and 39.3% for the full year [10] - Omnipod 5 is now available in 19 countries, with significant growth in Canada and Australia following its launch [11] - The company plans to enhance its product offerings, including the next-generation Omnipod 6, with pivotal data expected at ADA in June [16][17] 2026 Outlook - For Q1 2026, Insulet expects Omnipod revenue growth of 28% to 30% and total company revenue growth of 25% to 27% [19] - For the full year 2026, the company anticipates Omnipod revenue growth of 21% to 23% and total company revenue growth of 20% to 22% [20] - Management expects approximately 100 basis points of operating margin expansion in 2026, with a significant increase in R&D investment [21]